FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136993544> ?p ?o ?g. }

• W3136993544 abstract "Identifying markers capable of predicting outcomes in lung cancer patients treated with nivolumab represents a growing research interest. The combination of neutrophil‑to‑lymphocyte ratio (NLR) and body mass index (BMI) may help predict treatment efficacy. Thus, the present study aimed to investigate the influence of NLR and BMI on progression‑free survival (PFS) in non‑small‑cell lung cancer (NSCLC) patients treated with nivolumab. A retrospective study was made on 80 patients with NSCLC that were treated with nivolumab at the OncoHelp Oncology Center, Timisoara, Romania after platinum‑based chemotherapy, from January 2018 to April 2020. Patients were administered nivolumab at a dose of 3 mg/m² or 240 mg total dose, every 2 weeks. The predictive impact of NLR (baseline at 2 and 4 weeks after the start of nivolumab) and BMI for disease progression was assessed. Median PFS for subjects with NLR <3 before treatment was 18.5 weeks, while in subjects with NLR ≥3 was 14 weeks (P=0.50). Median PFS for subjects with NLR2 <3 at 2 weeks after treatment was 21 weeks, while in subjects with NLR2 ≥3, PFS was 14 weeks (P=0.17). Median PFS for subjects with NLR4 <3 at 4 weeks after treatment was 23 weeks, while in subjects with NLR4 ≥3, PFS was 19 weeks (P=0.33). Multivariate analysis for the association with PFS showed that baseline NLR, male sex and BMI were associated independently, thus we could develop a significant statistical model [AUROC=0.76, 95% CI (0.45‑0.89), P=0.03], a new predictive score for PFS. The assessment of NLR and BMI may represent simple and useful biomarkers; combining them and taking into consideration the male sex may predict PFS in patients with advanced NSCLC treated with nivolumab." @default.
• W3136993544 created "2021-03-29" @default.
• W3136993544 creator A5004788098 @default.
• W3136993544 creator A5009452590 @default.
• W3136993544 creator A5016925987 @default.
• W3136993544 creator A5022810247 @default.
• W3136993544 creator A5029343418 @default.
• W3136993544 creator A5040644849 @default.
• W3136993544 creator A5080155767 @default.
• W3136993544 creator A5082118171 @default.
• W3136993544 date "2021-03-22" @default.
• W3136993544 modified "2023-10-18" @default.
• W3136993544 title "Role of combining neutrophil‑to‑lymphocyte ratio and pretreatment body mass index in predicting progression‑free survival in patients with non‑small cell lung cancer treated with nivolumab" @default.
• W3136993544 cites W1534345915 @default.
• W3136993544 cites W1536926823 @default.
• W3136993544 cites W1570472500 @default.
• W3136993544 cites W1827997917 @default.
• W3136993544 cites W1892385952 @default.
• W3136993544 cites W1919200564 @default.
• W3136993544 cites W1982906652 @default.
• W3136993544 cites W1989111278 @default.
• W3136993544 cites W1998884240 @default.
• W3136993544 cites W2024861438 @default.
• W3136993544 cites W2044748328 @default.
• W3136993544 cites W2059273277 @default.
• W3136993544 cites W2065663086 @default.
• W3136993544 cites W2066671159 @default.
• W3136993544 cites W2085458222 @default.
• W3136993544 cites W2113017183 @default.
• W3136993544 cites W2117692326 @default.
• W3136993544 cites W2125520495 @default.
• W3136993544 cites W2125884672 @default.
• W3136993544 cites W2127997556 @default.
• W3136993544 cites W2141269240 @default.
• W3136993544 cites W2147286476 @default.
• W3136993544 cites W2155052327 @default.
• W3136993544 cites W2169838621 @default.
• W3136993544 cites W2214799754 @default.
• W3136993544 cites W2302719382 @default.
• W3136993544 cites W2581283430 @default.
• W3136993544 cites W2608165987 @default.
• W3136993544 cites W2623463260 @default.
• W3136993544 cites W2748959367 @default.
• W3136993544 cites W2786396800 @default.
• W3136993544 cites W2792273180 @default.
• W3136993544 cites W2898790194 @default.
• W3136993544 cites W2907028960 @default.
• W3136993544 cites W2925088208 @default.
• W3136993544 cites W2945791961 @default.
• W3136993544 cites W2988987639 @default.
• W3136993544 cites W2997651933 @default.
• W3136993544 cites W3012135573 @default.
• W3136993544 cites W3021491495 @default.
• W3136993544 cites W3025905835 @default.
• W3136993544 cites W3047255238 @default.
• W3136993544 doi "https://doi.org/10.3892/etm.2021.9958" @default.
• W3136993544 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8014982" @default.
• W3136993544 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33815599" @default.
• W3136993544 hasPublicationYear "2021" @default.
• W3136993544 type Work @default.
• W3136993544 sameAs 3136993544 @default.
• W3136993544 citedByCount "3" @default.
• W3136993544 countsByYear W31369935442022 @default.
• W3136993544 countsByYear W31369935442023 @default.
• W3136993544 crossrefType "journal-article" @default.
• W3136993544 hasAuthorship W3136993544A5004788098 @default.
• W3136993544 hasAuthorship W3136993544A5009452590 @default.
• W3136993544 hasAuthorship W3136993544A5016925987 @default.
• W3136993544 hasAuthorship W3136993544A5022810247 @default.
• W3136993544 hasAuthorship W3136993544A5029343418 @default.
• W3136993544 hasAuthorship W3136993544A5040644849 @default.
• W3136993544 hasAuthorship W3136993544A5080155767 @default.
• W3136993544 hasAuthorship W3136993544A5082118171 @default.
• W3136993544 hasBestOaLocation W31369935441 @default.
• W3136993544 hasConcept C121608353 @default.
• W3136993544 hasConcept C126322002 @default.
• W3136993544 hasConcept C143998085 @default.
• W3136993544 hasConcept C2776256026 @default.
• W3136993544 hasConcept C2776694085 @default.
• W3136993544 hasConcept C2777701055 @default.
• W3136993544 hasConcept C2777761686 @default.
• W3136993544 hasConcept C2778963024 @default.
• W3136993544 hasConcept C2780030458 @default.
• W3136993544 hasConcept C2780221984 @default.
• W3136993544 hasConcept C2780739268 @default.
• W3136993544 hasConcept C71924100 @default.
• W3136993544 hasConcept C90924648 @default.
• W3136993544 hasConceptScore W3136993544C121608353 @default.
• W3136993544 hasConceptScore W3136993544C126322002 @default.
• W3136993544 hasConceptScore W3136993544C143998085 @default.
• W3136993544 hasConceptScore W3136993544C2776256026 @default.
• W3136993544 hasConceptScore W3136993544C2776694085 @default.
• W3136993544 hasConceptScore W3136993544C2777701055 @default.
• W3136993544 hasConceptScore W3136993544C2777761686 @default.
• W3136993544 hasConceptScore W3136993544C2778963024 @default.
• W3136993544 hasConceptScore W3136993544C2780030458 @default.
• W3136993544 hasConceptScore W3136993544C2780221984 @default.
• W3136993544 hasConceptScore W3136993544C2780739268 @default.
• W3136993544 hasConceptScore W3136993544C71924100 @default.
• W3136993544 hasConceptScore W3136993544C90924648 @default.

• next